MSK Executive Director Gregory Baskin Turns Over His Equity in New Venture

New Venture- Equity

As reported in the New York Times by Katie Thomas and Charles Ornstein, Dr. Gregory Raskin who led Memorial Sloan Kettering ventures must now turn over his nearly $1.4 million equity stake in a new biotech spinoff due to the recent conflict of interest news coming out of this research institution.